OT-101 is named as an intervention in 2 current clinical trials in our USA register. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Oncotelic Inc. The most-studied condition is Malignant Pleural Mesothelioma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
NCT06079346 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma
|
Phase 2/3 | Recruiting | Oncotelic Inc. | USA |
|
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
NCT05425576 · Malignant Pleural Mesothelioma
|
Phase 2 | Not yet open | Oncotelic Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Oncotelic Inc. | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA register name OT-101 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Oncotelic Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how OT-101 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how OT-101 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists OT-101 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.